In hormone receptor-positive ( HR ) + disease , only high-Ki-67 tumors ( 20 % ) derived significant benefit from taxane-based therapy : hazard ratio = 0.39 ( 95 % CI 0.18-0 .82 ) for EC-Doc versus FEC ( test for interaction ; P = 0.01 ) .